PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
NCT ID: NCT06175832
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
60 participants
INTERVENTIONAL
2025-01-27
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CFA/PPOS cycle
Interventional stimulation
Elonva®
Single injection
Puregon®
Multiple injections
Gonapeptyl®
Double injection
Cerazette®
Oral tablet
rFSH / GnRH antagonist cycle
Conventional stimulation
Puregon®
Multiple injections
Orgalutran®
Multiple injections
Gonapeptyl®
Double injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Elonva®
Single injection
Puregon®
Multiple injections
Orgalutran®
Multiple injections
Gonapeptyl®
Double injection
Cerazette®
Oral tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Group 2: indication for IVF/ICSI and PGT-A
* First ovarian stimulation cycle
* Aged ≥ 18 and \< 41 years old at the time of first OPU
Exclusion Criteria
* expected poor ovarian response (Bologna Criteria)
* PCOS patients
* refusal to fill out questionnaires before, during and after treatment
* simultaneous participation in another clinical study
* untreated and uncontrolled thyroid dysfunction;
* current use of oral contraceptives, anti-psychotics, anti-epileptics or chemotherapy;
* pregnant or breastfeeding women. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon
INDUSTRY
University Hospital, Ghent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Ghent
Ghent, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dominic Stoop, Prof. dr.
Role: primary
Kathleen Wijnant, Msc
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-506694-35-00
Identifier Type: CTIS
Identifier Source: secondary_id
ONZ-2023-0299
Identifier Type: -
Identifier Source: org_study_id